[go: up one dir, main page]

WO2002056867A2 - Composition pharmaceutique a liberation lente contenant des antibiotiques $g(b)-lactame a efficacite therapeutique amelioree - Google Patents

Composition pharmaceutique a liberation lente contenant des antibiotiques $g(b)-lactame a efficacite therapeutique amelioree Download PDF

Info

Publication number
WO2002056867A2
WO2002056867A2 PCT/IN2002/000009 IN0200009W WO02056867A2 WO 2002056867 A2 WO2002056867 A2 WO 2002056867A2 IN 0200009 W IN0200009 W IN 0200009W WO 02056867 A2 WO02056867 A2 WO 02056867A2
Authority
WO
WIPO (PCT)
Prior art keywords
extended release
weight
pharmaceutical composition
release pharmaceutical
lactam antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2002/000009
Other languages
English (en)
Other versions
WO2002056867A3 (fr
Inventor
Rama Rao Pendyala
Podili Khadgapathi
Venkaiah Chowdary Nannapaneni
Venkateswara Rao Pavuluri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Priority to CA002435305A priority Critical patent/CA2435305A1/fr
Priority to JP2002557375A priority patent/JP2004520358A/ja
Priority to EP02701537A priority patent/EP1353651A2/fr
Priority to AU2002234868A priority patent/AU2002234868A1/en
Publication of WO2002056867A2 publication Critical patent/WO2002056867A2/fr
Publication of WO2002056867A3 publication Critical patent/WO2002056867A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Definitions

  • the invention disclosed is an oral pharmaceutical composition for extended release of active ingredient, at least one ⁇ -lactam antibiotic specifically intended for the release of drugs possessing a site-specific absorption upon oral administration, useful for maintaining the desired therapeutic concentration of active ingredient in blood for an extended time periods thus meeting the requirements for effective management of certain infectious diseases minimizing the dosing frequency and patient intervention.
  • the invention also includes a process for preparation of the pharmaceutical composition.
  • the oral pharmaceutical composition of the invention is a polymeric matrix containing at least one ⁇ -lactam antibiotic along with other excipients and additives, either in the form of a tablet or a capsule or a dry syrup for reconstitution at the time of administration.
  • the relationship between pharmacokinetic and pharmacodynamic parameters depends on three elements: the pathogen, the host and specific antimicrobial agent.
  • the Post-antibiotic effect of the drug is another pharmacodynamic parameter that has to be considered in determining the optimal dosage regimen.
  • the present invention is based on our finding that invitro dissolution profile of an antibiotic from an extended release composition containing an antibiotic or its prodrugs, coated with release modulating polymer which maintains the integrity of the dosage form in varying pH conditions of gastrointestinal tract, compressed into tablets or filled into gelatin capsules or as a dry syrup for reconstitution, when administered orally to humans for the treatment of infectious diseases provides a therapeutic concentration over an extended period of time with better patient compliance.
  • This provides preprogrammed, unattended delivery of drug at a rate and for a time period meeting to therapeutic need.
  • Such drug delivery system minimizes patients intervention and maximizes compliance with the prescribed dose regimen.
  • the present invention relates to a pharmaceutical composition in the form of an extended release oral drug delivery system comprising an active ingredient such as ⁇ -lactam antibiotic agent having a specific absorption site in gastrointestinal tract in combination with a polymeric material forming a matrix along with other pharmaceutically acceptable additives, wherein at least 25% of active antibiotic agent is released from said matrix within 0.5 to 1.0 hour after oral administration and a substantial amount of remaining active ingredient over an extended period, but within 2 to 5 hours after administration.
  • This facilitates the complete absorption of the active ingredient before it crosses the "absorption window" where an active carrier mediated transport takes place across the g.i.t. membrane.
  • the concept of present invention can be effectively applied to any pharmaceutical agent which has an "absorption window".
  • the drug granules may consist of at least one ⁇ -lactam antibiotic along with other pharmaceutically acceptable additives, a release modulating polymer with plasticizer and anti- adherent.
  • the pharmaceutical composition of the invention can be in the form of (a) tablet containing drug granules, diluents or fillers, lubricants (b) capsule containing drug granules, fillers, lubricants or (c) dry syrup containing granules admixed with additives such as sweetners, flavours etc, suitable for oral administration upon reconstitution.
  • the main objective of the present invention is to provide a novel extended release pharmaceutical composition containing antibacterial substance selected particularly from ⁇ - lactam antibiotics which are useful for the treatment of infectious diseases.
  • Another objective of the present invention is to provide a novel extended release pharmaceutical composition containing an antibiotic which is effective for a longer period of time when compared to the conventional immediate release pharmaceutical composition.
  • Still another objective of the present invention is to provide a novel pharmaceutical composition which is therapeutically effective over an extended period of at least 10 -14 hours, providing initial dose of active substance for absorption immediately i.e. within 0.5 to 1.0 hour and to release substantial amount of the remaining active substance at a rate sufficient to maintain the drug concentration in therapeutically effective range for a desired period of time.
  • the present invention provides a novel oral extended release pharmaceutical composition containing an antibiotic, useful for the treatment of infectious diseases comprising the drug in the form of a tablet or capsule or dry syrup for reconstitution made from the granules of drug coated with release modulating polymer composition.
  • the formulation also contain necessary pharmaceutical additives.
  • the invention also provides a process for the preparation of the above said pharmaceutical composition.
  • an extended release pharmaceutical composition containing a ⁇ -lactam antibiotic capable of providing the required initial dose followed by extended release of the remaining drug where in the active substance is selected from penicillins or cephalosporins.
  • an extended Pharmaceutical release composition wherein the said ⁇ -lactam antibiotic drug is selected from penicillins such penicillin V, penicillin G, amoxicillin, ampicillin, cloxacillin, oxacillin, nafcilin, and derivatives thereof or cephalosporins such as cefadroxil, cefixime,
  • the amount of drug employed may range from 500.0 to 900. Omg more preferably 550.0 to 800.0 mg per gram of drug granules.
  • the polymers used are selected from cellulose derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, ethyl cellulose or methacrylic acid derivatives such as poly(methacrylic acid, methyl methacrylate) (1:1) and poly(methacrylic acid ethylacrylate) (1:1) (Eudragit L100 and Eudragit L100-55) and the like.
  • the amount of polymer employed may range from about 20.0mg to about 400.0mg more preferably 25. Omg to 250.0mg per gram of drug granules.
  • the plasticizer is selected from among phthalate derivatives such as diethyl phthalate, dipropyl phthalate, dioctyl phthalate, dibutyl phthalate, or glycol derivatives such as propylene glycol, polyethylene glycols of molecular weight ranging from 200 - 6000, or triethyl citrate or triacetin or a mixture thereof, the amount of which may range from about 10.0% to about 30.0% by weight of the polymer.
  • the anti-adherents used are selected from talc, magnesium stearate, calcium carbonate, magnesium carbonate, the amount of which may range from about 10.0% to about 30.0% by weight of the polymer.
  • the granular matrix is formulated as a unit dosage form of a tablet or a capsule or in the form of a dry syrup for reconstitution at the time of administration.
  • the tablets and capsules contain pharmaceutical additives selected from diluents such as starch, lactose, microcrystalline cellulose, dicalcium phosphate or mixture thereof and lubricants such as talc, hydrogenated castor oil, magnesium stearate, stearic acid, calcium stearate, zinc stearate or a mixture thereof.
  • the amount of diluents may range from about 20.0 to about 500.0 mg, more preferably 50.0 to 400.0mg per gram of drug granules.
  • the amount of lubricant may range from about 5.0 to about 50.0mg more preferably 10.0 to 40.0mg per gram of drug granules.
  • the dry syrup dosage units contain pharmaceutically acceptable additives selected from sweeteners such as sucrose, glucose, aspartame, sodium saccharin, N-methyl glycerrhezinate, fructose; flavours such as pineapple, strawberry, banana, vanilla, orange, mango, raspberry; colours such as titanium dioxide, erythrosine, brilliant blue, indigo carmine, tartrazine, ponceau 4R, sunset yellow, quinoline yellow, red oxide of iron, yellow oxide of iron;
  • sweeteners such as sucrose, glucose, aspartame, sodium saccharin, N-methyl glycerrhezinate, fructose
  • flavours such as pineapple, strawberry, banana, vanilla, orange, mango, raspberry
  • colours such as titanium dioxide, erythrosine, brilliant blue, indigo carmine, tartrazine, ponceau 4R, sunset yellow, quinoline yellow, red oxide of iron, yellow oxide of iron;
  • preservatives such as methyl paraben, propyl paraben and their sodium salts
  • buffers and flavour enhancers such as citric acid, sodium citrate and the like
  • antioxidants such as sodium sulphite, sodium bisulphite, sodium metabisulphite, sodium benzoate, butylated hydroxy toluene, butylated hydroxy anisole and the like.
  • the invention also provides a process for the preparation of the above said composition, which comprises i) Preparation of granules comprising drug. ii) Coating of the granules with a polymer dissolved in a mixture of organic solvents along with a plasticizer and anti-adherent. iii) Formulating the granules into tablets or capsules or dry syrup for reconstitution with suitable pharmaceutical additives.
  • the present invention provides a method for preparing the granules by dry granulation or wet granulation employing polymer solution in an organic solvent or blend of solvents.
  • the granules are further coated with a release modulating polymeric composition in a blend of organic solvents such as acetone, ethyl alcohol, isopropyl alcohol, methylene chloride and the like.
  • the granules are admixed with diluents and lubricants followed by either compression into tablets on a rotary compression machine or filled in to hard gelatin capsules on a capsule- filling machine.
  • the dry syrup may be prepared by admixing the granules with sweeteners, flavours, colourants, preservatives, antioxidants and buffers and flavour enhancers.
  • the dosage form described herein provides controlled drug entry into systemic circulation via gastrointestinal tract. It has advantages over conventional dosage forms for systemic therapy.
  • the rationale for such dosage form is based on its capability of maintaining drug concentrations in blood within a range that selectively elicits desired therapeutic effects over an extended time period in comparison to conventional dosage forms.
  • composition mg / g
  • Hydroxypropyl methylcellulose was dissolved in a blend of isopropyl alcohol and acetone along with diethyl phthalate and dispersed talc in it.
  • the compacted granules of ampicillin trihydrate were coated with the polymer composition and dried at 50°C.
  • composition mg / g
  • the ampicillin coated granules were mixed with ampicillin trihydrate granules, starch and microcrystalline cellulose powder and lubricated with talc and magnesium stearate. The lubricated granules were compressed into tablets on a rotary tablet press.
  • Stage 1 Composition mg / g
  • Poly(methacrylic acid, methyl methacrylate) was dissolved in a blend of isopropyl alcohol and acetone along with triethyl citrate and dispersed talc in it.
  • the compacted granules of cefadroxil monohydrate were coated with the polymer composition and dried at 50°C.
  • composition mg / g
  • cefadroxil coated granules were mixed with cefadroxil granules, starch and microcrystalline cellulose powder and lubricated with magnesium stearate. The lubricated granules were compressed into tablets on a rotary tablet press. EXAMPLE -HI
  • composition mg / g
  • Cellulose acetate phthalate was dissolved in a blend of isopropyl alcohol and methylene chloride along with diethyl phthalate and dispersed talc in it.
  • the compacted granules of cloxacillin sodium containing hydroxypropyl methylcellulose were coated with the polymer composition and dried at 50°C.
  • composition mg / g
  • the starch, dicalcium phosphate and microcrystalline cellulose powder were mixed and granulated with starch paste.
  • the wet mass was passed through 14# and dried at 65°C.
  • the cloxacillin coated granules were mixed with the above dry granules along with cloxacillin sodium granules and lubricated with magnesium stearate.
  • the lubricated granules were filled into hard gelatin capsules on a capsule-filling machine.
  • composition mg / g
  • Sucrose was milled to a fine grade and mixed with other ingredients which are previously sifted through 30# and finally mixed with the cefuroxime granules. The dry mixture was filled in to unit dose packs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique orale à libération lente contenant au moins un antibiotique β-lactame, destinée à libérer le médicament pendant une longue période lors de son administration. Cette composition pharmaceutique convient pour maintenir la concentration thérapeutique souhaitée du principe actif dans le sang pendant de longues périodes, remplissant ainsi les conditions permettant de gérer efficacement des maladies infectieuses. Cette composition pharmaceutique se présente sous forme de cachet, de capsule ou de sirop sec dont la reconstitution liquide se fait au moment de l'administration, et elle libère le principe actif en dose initiale et en dose de maintenance à un débit spécifique. Cette invention concerne aussi un processus de préparation de cette composition pharmaceutique à libération lente contenant des antibiotiques β-lactame.
PCT/IN2002/000009 2001-01-18 2002-01-18 Composition pharmaceutique a liberation lente contenant des antibiotiques $g(b)-lactame a efficacite therapeutique amelioree Ceased WO2002056867A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002435305A CA2435305A1 (fr) 2001-01-18 2002-01-18 Composition pharmaceutique a liberation lente contenant des antibiotiques .beta.-lactame a efficacite therapeutique amelioree
JP2002557375A JP2004520358A (ja) 2001-01-18 2002-01-18 改良された治療効能を有するβ−ラクタム抗生物質を含む徐放性薬剤組成物
EP02701537A EP1353651A2 (fr) 2001-01-18 2002-01-18 Compositions pharmaceutiques a liberation lente contenant des antibiotiques beta-lactame
AU2002234868A AU2002234868A1 (en) 2001-01-18 2002-01-18 Extended release pharmaceutical compositions containing beta-lactam antibiotics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN58/MAS/2001 2001-01-18
IN58CH2001 2001-01-18

Publications (2)

Publication Number Publication Date
WO2002056867A2 true WO2002056867A2 (fr) 2002-07-25
WO2002056867A3 WO2002056867A3 (fr) 2003-03-06

Family

ID=11096990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2002/000009 Ceased WO2002056867A2 (fr) 2001-01-18 2002-01-18 Composition pharmaceutique a liberation lente contenant des antibiotiques $g(b)-lactame a efficacite therapeutique amelioree

Country Status (4)

Country Link
EP (1) EP1353651A2 (fr)
JP (1) JP2004520358A (fr)
CA (1) CA2435305A1 (fr)
WO (1) WO2002056867A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843880A1 (fr) * 2002-09-02 2004-03-05 Flamel Tech Sa Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
FR2872044A1 (fr) * 2004-06-28 2005-12-30 Flamel Technologies Sa Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
EP1855647A4 (fr) * 2005-03-04 2010-11-17 Intelgenx Corp Forme de dosage oral pharmaceutique à libération différée et procédé de fabrication idoine
CN109260220A (zh) * 2018-11-28 2019-01-25 重庆华森制药股份有限公司 一种牡蛎碳酸钙颗粒的制备方法
CN113440530A (zh) * 2021-07-08 2021-09-28 广州白云山医药集团股份有限公司白云山制药总厂 一种头孢克肟药物及其制备方法
CN113908133A (zh) * 2021-11-29 2022-01-11 河南省儿童医院郑州儿童医院 一种头孢克肟缓释片及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114939113A (zh) * 2022-06-01 2022-08-26 澳美制药(苏州)有限公司 青霉素v钾片及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843880A1 (fr) * 2002-09-02 2004-03-05 Flamel Tech Sa Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
FR2872044A1 (fr) * 2004-06-28 2005-12-30 Flamel Technologies Sa Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
WO2006010868A1 (fr) * 2004-06-28 2006-02-02 Flamel Technologies Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
EP1855647A4 (fr) * 2005-03-04 2010-11-17 Intelgenx Corp Forme de dosage oral pharmaceutique à libération différée et procédé de fabrication idoine
CN109260220A (zh) * 2018-11-28 2019-01-25 重庆华森制药股份有限公司 一种牡蛎碳酸钙颗粒的制备方法
CN113440530A (zh) * 2021-07-08 2021-09-28 广州白云山医药集团股份有限公司白云山制药总厂 一种头孢克肟药物及其制备方法
CN113440530B (zh) * 2021-07-08 2023-08-08 广州白云山医药集团股份有限公司白云山制药总厂 一种头孢克肟药物及其制备方法
CN113908133A (zh) * 2021-11-29 2022-01-11 河南省儿童医院郑州儿童医院 一种头孢克肟缓释片及其制备方法
CN113908133B (zh) * 2021-11-29 2023-11-03 河南省儿童医院郑州儿童医院 一种头孢克肟缓释片及其制备方法

Also Published As

Publication number Publication date
EP1353651A2 (fr) 2003-10-22
WO2002056867A3 (fr) 2003-03-06
JP2004520358A (ja) 2004-07-08
CA2435305A1 (fr) 2002-07-25

Similar Documents

Publication Publication Date Title
US10285944B2 (en) Gastroresistant pharmaceutical formulations containing rifaximin
JP3699122B2 (ja) 新規な経口用の医薬使用形態
US7029701B2 (en) Composition for the treatment and prevention of ischemic events
US6767557B2 (en) Taste masked pharmaceutical compositions
US20110020408A1 (en) multilayered modified release formulation comprising amoxicillin and clavulanate
MXPA96004354A (en) New form of pharmaceutical dosage or
US20090111788A1 (en) Antibiotic compositions of modified release and process of production thereof
US20220062188A1 (en) All-in-one fixed-dose combination for treating helicobacter pylori infection
AU5880200A (en) Taste masked pharmaceutical liquid formulations
US20060110445A1 (en) Dispersible tablet for oral administration
WO2002056867A2 (fr) Composition pharmaceutique a liberation lente contenant des antibiotiques $g(b)-lactame a efficacite therapeutique amelioree
JP2008504352A (ja) マイクロカプセル形態の抗生物質を主成分とする製剤処方
WO2004000281A1 (fr) Comprimes a desagregation rapide
WO2011093829A1 (fr) Compositions effervescentes comprenant du cefixime et de l'acide clavulanique comme principes actifs
US20090088415A1 (en) Controlled release pharmaceutical compositions
EP2515905A1 (fr) Formulations pharmaceutiques comprenant une céphalosporine de troisième génération et de l'acide clavulanique
GR1008992B (el) Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης
KR100475260B1 (ko) 높은양의약을함유하는,신속-붕해되고신속-용해되는조성물제조용과립
TR201511982A2 (tr) Anti̇bakteri̇yel formülasyonlar
US20110160156A1 (en) Pharmaceutical Composition for the Eradication of Helicobacter Pylori and Preparation Method Thereof
KR100523082B1 (ko) 쓴 맛이 은폐된 세푸록심악세틸 제제의 제약조성물 및 그의 제조방법
EP1785135A1 (fr) Nouvelles compositions galéniques stabilisées comprenant du lanzoprazole et leur préparation
KR20040098907A (ko) 클라불란산과 베타 락탐계 항생물질을 포함하는이중방출형 제제
MXPA06007781A (en) Controlled release pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002557375

Country of ref document: JP

Ref document number: 2435305

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002701537

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002701537

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002701537

Country of ref document: EP